" class="no-js "lang="en-US"> Clearsense Acquires Plug-and-Play AI Analytics Firm - Medtech Alert
Monday, February 26, 2024

Clearsense Acquires Plug-and-Play AI Analytics Firm

Clearsense, an AI-powered data analytics platform company that translates healthcare data into highly consumable insights, today announced the acquisition of Compellon, a privately-held, plug-and-play AI analytics company based in Lake Forest, California. The multi-patented Compellon technology uses AI to re-engineer predictive modeling, removing the technical burden from users. The technology is a hand in glove complement to the end-to-end Clearsense platform which cleans, organizes, and enriches data to transform it into ready-to-use, insights that users trust.

Clearsense Co-founder and Chief Innovation Officer Charles Boicey stated, “Compellon’s game changing technology directly supports our mission to rapidly make data analytics nearly as easy as a Google query for clinicians and everyday users.” Boicey added, “With this solution, clinicians and other users can bypass the arduous, time-consuming manual process of testing hypothesis, and see results in hours instead of weeks or more.” The Compellon predictive modeling solution is a cornerstone of the Clearsense advanced analytics and research platform.

Advanced end-to-end solutions like Clearsense are beckoning in a new era of the citizen data scientist in healthcare by empowering everyday users to solve business and clinical problems without the technical expertise previously required. 

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more